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Abstract
Introduction: Oral pre-exposure prophylaxis (PrEP) for HIV prevention has been proven to significantly reduce new HIV
infections yet scale-up has been slow. As contexts continue to adjust to make space for PrEP, it is crucial to understand the
perspectives and experiences of potential end-users. In order to inform PrEP and demand creation interventions, this paper
examines personal perspectives on adopting and using PrEP among HIV at-risk populations in sub-Saharan Africa.
Methods: Using the principles of a scoping review in July 2018, we explored the extent, range, and nature of published litera-
ture regarding PrEP uptake and use among; men who have sex with men, HIV serodiscordant couples, adolescent girls and
young women, pregnant and breastfeeding women, women partners of migrant workers; and people who use drugs. Steps
included: identification of the research question; identification of relevant studies; study selection; charting the data; and colla-
tion – summarizing and reporting results. PubMed and PsycInfo were searched for papers relating to PrEP uptake and use in
sub-Saharan Africa. Resulting papers were reviewed with data extracted and compiled in Excel for analysis. A broad content
analysis was conducted and organized into high-level themes.
Results and discussion: Thirty-five papers were included in this review. There was little opposition in general to oral PrEP;
however, there were significant nuances in its broader acceptability, applicability, and usability. We identified five themes within
which these are discussed. These relate to balancing complexities of personal empowerment and stigma; navigating complex
risk environments; influences of relationships and partners; efficacy and side effects; and practicalities of use. This body of
research suggests that while product attributes and the logistics of PrEP delivery and use are important topics, it is vital to
consider stigma, the interactions of PrEP use with relationships, and the need for broader understanding of ARVs for preven-
tion versus treatment.
Conclusions: Planning for, programming and promoting the adoption of oral PrEP necessitates a deeper understanding of
end-user priorities in order to ensure successful interventions. This review illustrates the nuances facilitating or deterring PrEP
use that may affect the larger effort of PrEP scale-up.
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1 | INTRODUCTION
Oral pre-exposure prophylaxis (PrEP) for HIV prevention has
been proven to significantly reduce new HIV infections in effi-
cacy trials [1], yet introduction has been slow. PrEP is being
implemented in nearly 50 countries to varying degrees [2],
though predominantly in phased implementation approaches
limiting service delivery sites and access [3,4]. This has
particularly been the case in sub-Saharan Africa owing largely
to strained national health budgets.
Epidemiological modelling suggests that PrEP will be most
cost effective if offered to those at highest risk [5–9], and
where PrEP has gained momentum both in community
support and scale-up among World Health Organization
(WHO) recommended higher risk populations [10], such as
Australia and the United Kingdom, significant falls in HIV inci-
dence have been observed [11,12]. Conversely, many of the
phased approaches have come with limited demand genera-
tion and communications strategies [3]. These barriers perpet-
uate challenges for uptake and effective use of PrEP among
current and potential end-users. Rendering the UNAIDS goal
of reaching three million people at high risk with PrEP by
2020 unlikely [13].
As programmes shift to integrate PrEP, it is crucial that we
understand the perspectives of those taking up and using
PrEP in order to demonstrate demand, facilitate use, and
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mitigate multi-level barriers. At the centre of successful pro-
ven theories and practices concerning intervention scale-up
are time, communication and user-acceptability [14]. Accept-
ability can be defined in a myriad of ways, but the key ele-
ments, also reflected in this paper, include: (1) the applicability
of the innovation (oral PrEP), or the relevance and responsive-
ness of the innovation to the lives of those who need it; as
well as, (2) the acceptability which speaks to a more internal,
emotional, user-centred [15]) perspective. Fundamentally, it
can be argued that the uptake and continued use of PrEP will
occur at scale only if populations/end-users are at the centre
and PrEP is: a known product, meets needs, can be integrated
into everyday lives. Our previous research relating to female
initiated HIV prevention technologies demonstrated how, his-
torically, interventions have focused on the easiest goals, such
as ensuring clinical access and examining product attributes
[16]. However, it was often personal and relationship con-
cerns, such as comfort, trust, and sexual pleasure, in addition
to practicalities, that actually played a central role in uptake
and use [16]. As the rollout of PrEP continues, it is essential
that researchers and implementers continue to examine how
it is influencing and changing the lives of end-users.
In this review, we synthesize published literature concerning
both the actual experience of using PrEP and the perspectives
of potential end-users (which we refer to as “theoretical use”).
This work builds on previous mixed method and qualitative
reviews [16,17]. Our aim is to elucidate the broad perception
or experience of PrEP, including motivations for use, barriers
to uptake or continued use, and the manner in which it
impacts (or could impact) everyday life. We seek to highlight
current gaps in the literature to facilitate the scale-up of PrEP.
2 | METHODS
This research utilizes scoping review methods to establish the
extent, range, and nature of published literature assessing the
experience of PrEP uptake and use, or the theoretical per-
spective of use, in terms of applicability and acceptability [18].
Often, but not always, a forerunner to full systematic reviews,
scoping reviews provide a means of rapidly appraising emerg-
ing subject matter and can provide a mechanism by which
complex findings are summarized for policy makers and practi-
tioners. Arksey and O’Malley outline five necessary phases:
identification of the research question; identification of rele-
vant studies; study selection; charting the data; and collation,
which summarizes and reports results [18].
Our review of the literature was informed by the question,
“What are the lived experiences or personal perspectives of
those HIV at-risk populations in sub-Saharan Africa adopting
and using PrEP?” Acknowledging the growing interest and
motivation to expand review methods to allow for less rigid,
and more inclusive, synthesis of data [19], we sought to com-
bine data from mixed methods research (i.e. both quantitative
and qualitative) as well as lessons learned from pre-cursor
studies which addressed theoretical rather than actual accept-
ability and use of PrEP. We also sought to look across HIV at-
risk populations to explore where there may be commonalities
or differences in perspectives on PrEP.
The search was conducted in August 2018 in PubMed and
PsycInfo using the keywords: Africa (and all countries
classified in the UN region), pre-exposure prophylaxis (PrEP),
Acceptability, Willingness, Barriers, Facilitators, Use and Pref-
erences. Papers were included if they: focused on theoretical
or actual use of PrEP and took place in Africa. After dedupli-
cation, the search returned 68 papers, which were divided
among all three authors for review. Thirty-three were
excluded for the following reasons: they had no bearing on
the topic; did not include primary, empirical data (e.g. was a
review or a study protocol); contained only research relating
to providers, policy maker or other perspectives on PrEP; or
research took place outside of Africa. There were no date or
language exclusions. Note that studies only emerged from
sub-Saharan Africa.
All three authors extracted and compiled relevant data in a
spreadsheet. Bibliographic data, study populations and study
locations, as well as whether the study involved actual use or
theoretical perspectives of PrEP (e.g. “If PrEP were to be avail-
able in your area, would you wish to use it?” and associated
data) were recorded in addition to themes covered in the
papers. Once all data were compiled, we conducted a broad
content analysis [20]. Codes, concepts, and ideas were docu-
mented, before being organized into relevant meta-themes.
Authors then reviewed the consolidated dataset of all data
and author findings. A limited subset of the final list of
included papers was reviewed by two of the authors to
ensure agreement of findings. This analysis also built upon a
previous adapted meta-ethnography (led by two of the
authors of this paper), which developed a framework for
understanding user-perspectives of female initiated biomedical
HIV prevention products [16]. Note that where a mixed-
methods paper was included, the quantitative data were
incorporated to support the qualitative themes (e.g. such as
perspectives on risk compensation and statistical analyses
showing none was found). Additionally, there is no quality
assessment of data since this review is focused on exploring
data to elucidate current understanding of PrEP and identify
areas for further research. Finally, since the results and dis-
cussion are combined in this paper, additional supporting
reviews and data papers are included in the sections that
follow.
3 | RESULTS AND DISCUSSION
This review generated 35 papers primarily from studies of
potential but not actual PrEP users, from qualitative compo-
nents of product efficacy studies, or from participants in
demonstration projects undertaken in sub-Saharan Africa,
where HIV infection remains both common and very highly
stigmatized. These studies include a range of populations
including male and female sex workers; men who have sex
with men (MSM); HIV serodiscordant couples; adolescent girls
and young women (AGYW); pregnant and breastfeeding
women; women partners of migrant workers; and people who
use drugs (PWUD). Included papers are listed in Table 1.
Very few studies reported clear opposition to PrEP as an
HIV prevention tool, although some generated evidence of
community distrust of study/trial designs or of the concept of
PrEP itself [21]. Theoretical studies among potential end-users
typically found high acceptability of PrEP [22–31]. By including
the theoretical research, a range of regimens are included in
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Table 1. Review papers included
Authors Title Pub year
Type of PrEP use
(theoretical/actual) Population(s) Location
Agot et al. Accuracy of self-report and pill count measures
of adherence in the FEM-PrEP clinical trial:
implication for future HIV-prevention trials
2015 Actual High-risk adult
women
Kenya, South
Africa,
Tanzania
Amico et al. Experiences with HPTN 067/ADAPT study-
provided open-label PrEP among women in
Cape Town: facilitators and barriers within a
mutuality framework
2017 Actual High-risk adult
women
South Africa
Bazzi et al. Perspectives on biomedical HIV prevention
options among women who inject drugs in
Kenya
2018 Theoretical Women who inject
drugs
Kenya
Busisiwe
et al.
Influences on visit retention in clinical trials:
insights from qualitative research during the
VOICE trial in Johannesburg, South Africa
2014 Actual High-risk adult
women
South Africa
Carroll et al. Gendered differences in the perceived risks and
benefits of oral PrEP among HIV
serodiscordant couples in Kenya
2016 Actual Serodiscordant
couples
Kenya, Uganda
Corneli et al. Motivations for reducing other HIV risk-
reduction practices if taking pre-exposure
prophylaxis: findings from a qualitative study
among women in Kenya and South Africa
2015 Theoretical High-risk adult
women
Kenya, South
Africa
Corneli et al. Facilitators of adherence to the study pill in the
FEM-PrEP clinical trial
2015 Theoretical High-risk adult
women
Kenya, South
Africa
Corneli et al. Participants’ explanation for nonadherence in
the FEM-PrEP trial
2016 Actual High-risk adult
women
Kenya, South
Africa
Corneli et al. A descriptive analysis of perceptions of HIV risk
and worry about acquiring HIV among FEM-
PrEP participants who seroconverted in
Bondo, Kenya and Pretoria, South Africa
2014 Actual High-risk adult
women
Kenya, South
Africa
Corneli et al. The science of being a study participant: FEM-
PrEP participants’ explanations for
overreporting adherence to the study pills
and for the whereabouts of unused pills
2015 Actual High-risk adult
women
Kenya, South
Africa
Eakle et al. Exploring acceptability of oral PrEP prior to
implementation among female sex workers in
South Africa
2018 Theoretical FSW South Africa
Luecke et al. Stated product formulation preferences for HIV
pre-exposure prophylaxis among women in
the VOICE-D (MTN-003D) study
2016 Actual and theoretical High-risk adult
women
South Africa
Fowler et al. Attitudes of serodiscordant couples towards
antiretroviral-based HIV prevention strategies
in Kenya: a qualitative study
2014 Theoretical Serodiscordant
couples
Kenya
Kibengo et al. Safety, adherence and acceptability of
intermittent tenofovir/emtricitabine as HIV
pre-exposure prophylaxis (PrEP) among HIV-
uninfected Ugandan volunteers living in HIV-
serodiscordant relationships: a randomized,
clinical trial
2013 Actual Serodiscordant
couples
Uganda
Mutua et al. Safety and adherence to intermittent pre-
exposure prophylaxis (PrEP) for HIV-1 in
African men who have sex with men and
female sex workers
2012 Actual MSM, FSW Kenya
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Table 1. (Continued)
Authors Title Pub year
Type of PrEP use
(theoretical/actual) Population(s) Location
Guest et al. Acceptability of PrEP for HIV Prevention Among
Women at High Risk for HIV
2010 Actual High risk adult
women
Ghana
Falcao et al. Willingness to use short-term oral pre-exposure
prophylaxis (PrEP) by migrant miners and
female partners of migrant miners in
Mozambique
2017 Actual Male migrant miners
and female
partners
Mozambique
Hartmann
et al.
Motivated Reasoning and HIV Risk? Views on
Relationships, Trust, and Risk from Young
Women in Cape Town, South Africa, and
Implications for Oral PrEP
2018 Theoretical Young women South Africa
Namey et al. When and why women might suspend PrEP use
according to perceived seasons of risk:
implications for PrEP-specific risk-reduction
counselling.
2016 Theoretical Sexually active
women at higher
risk of HIV
Kenya, South
Africa
Mack et al. The importance of choice in the rollout of ARV-
based prevention to user groups in Kenya and
South Africa: a qualitative study
2014 Theoretical FSW, Serodiscordant
couples, AGYW,
Kenya, South
Africa
Ngure et al. I Knew I Would Be Safer. Experiences of
Kenyan HIV Serodiscordant Couples Soon
After Pre-Exposure Prophylaxis (PrEP)
Initiation
2016 Actual Serodiscordant
couples
Kenya
Mugo et al. Understanding Adherence to Daily and
Intermittent Regimens of Oral HIV Pre-
exposure Prophylaxis Among Men Who Have
Sex with Men in Kenya
2015 Actual MSM Kenya
Pintye et al. HIV-Uninfected Kenyan Adolescent and Young
Women Share Perspectives on Using
Preexposure Prophylaxis During Pregnancy
2018 Theoretical Young pregnant or
post-partum
women
Kenya
Pintye et al. “I Did Not Want to Give Birth to a Child Who
has HIV”: Experiences Using PrEP During
Pregnancy Among HIV-Uninfected Kenyan
Women in HIV-Serodiscordant Couples
2017 Actual Serodiscordant
couples
Kenya
Restar et al. Perspectives on HIV Pre- and Post-Exposure
Prophylaxes (PrEP and PEP) Among Female
and Male Sex Workers in Mombasa, Kenya:
Implications for Integrating Biomedical
Prevention into Sexual Health Services
2017 Theoretical Young male and
female sex
workers
Kenya
Roberts et al. Intimate Partner Violence and Adherence to
HIV Pre-exposure Prophylaxis (PrEP) in
African Women in HIV Serodiscordant
Relationships: A Prospective Cohort Study
2016 Actual Negative women in
serodiscordant
relationships
Kenya, Uganda
Robinson
et al.
“How I Wish This Thing Was Initiated 100
Years Ago!” Willingness to Take Daily Oral
Pre-Exposure Prophylaxis among Men Who
Have Sex with Men in Kenya
2016 Theoretical MSM Kenya
Shaver et al. Comparing Provider and Client Preferences for
HIV Prevention Services in South Africa
among Men Who Have Sex with Men
2017 Theoretical and actual MSM South Africa
Sithole et al. HIV prevention needs for men who have sex
with men in Swaziland
2017 Theoretical MSM Swaziland
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the review including: oral daily and intermittent (the definition
of which is particular to the given study), as well as emerging
injectable and vaginal ring products.
One theoretical study suggested a limited motivation to
take PrEP in light of HIV treatment needs and few pre-exist-
ing social norms relating to prophylactic medication [24]. How-
ever, no clinical trial or demonstration project reported
significant challenges with recruitment, potentially due to
financially incentivized participation and/or provision of higher
calibre health care as compared to the norm [32]. Some stud-
ies reported altruism [32] or “Ubuntu,” [21] the concept of
contributing something positive to your community, as
research motivators to advance HIV prevention. Actual use
research also found PrEP acceptability to be high but also
described a range of benefits and problems that can arise,
which we address under five key themes below.
3.1 | Balancing the complexities of personal
empowerment and potential stigma
The potential to use anti-retroviral therapy (ART) to prevent
HIV infection seemed counter-intuitive to some potential
users where prior experience was focused on treating sick
people with ART. When PrEP was described to a na€ıve poten-
tial user, concern was common that taking the same medica-
tions used to treat diagnosed HIV will mean “people will just
assume I have HIV” [23]. Such findings suggest that HIV
related stigma is still so pervasive that it may pose a challenge
to PrEP provision whether or not it is linked to services also
providing ART to HIV positive people [33].
Several studies suggest that PrEP is conflated with ART not
just in personal understandings of PrEP but in expectations of
how others will respond, generating fear of HIV-related stigma
and discrimination. This potential stigma has been highlighted
among MSM in Kenya [23]; women who inject drugs in Kenya
[30]; female sex workers in Kenya and South Africa [34,35];
female partners of migrant workers returning to Mozambique
for short periods [36]; and women at high risk of HIV infec-
tion in South Africa [37–39]. Participants in all these studies
broadly welcomed the opportunity to avoid HIV infection but
were apprehensive about being seen to take ART. All feared
being identified as HIV infected which would lead to social
isolation and other harms. Some went to great lengths to dis-
guise their involvement in research and were secretive about
using PrEP with regular partners and immediate family, even
when this made adherence very difficult. These fears could
ultimately affect the impact of PrEP where related use
becomes limited.
Conversely, PrEP use in some studies raised hope and
offered potentially transformative opportunities. Participants
cited increased control over one’s sexual health [40] and hope
in avoiding infection as values of taking PrEP, especially among
women with limited trust in the monogamy of their partner
and limited power to ensure condom use. This is also true for
men and women involved in selling sex or in known serodis-
cordant relationships. By offering negative partners of people
Table 1. (Continued)
Authors Title Pub year
Type of PrEP use
(theoretical/actual) Population(s) Location
Van der Elst
et al.
High acceptability of HIV pre-exposure
prophylaxis but challenges in adherence and
use: qualitative insights from a phase I trial of
intermittent and daily PrEP in at-risk
populations in Kenya
2012 Actual MSM, FSW Kenya
van der
Straten
et al.
Perspectives on use of oral and vaginal
antiretrovirals for HIV prevention: the
VOICE-C qualitative study in Johannesburg,
South Africa
2014 Actual High-risk adult
women
South Africa,
Uganda,
Zimbabwe
van der
Straten
et al.
Women’s experiences with oral and vaginal pre-
exposure prophylaxis: the VOICE-C qualitative
study in Johannesburg, South Africa
2014 Actual High-risk adult
women
South africa,
Uganda,
Zimbabwe
Ware et al. Lay Social Resources for Support of Adherence
to Antiretroviral Prophylaxis for HIV
Prevention Among Serodiscordant Couples in
sub-Saharan Africa: A Qualitative Study
2015 Actual Serodiscordant
couples
Uganda
Ware et al. Integrated delivery of antiretroviral treatment
and pre-exposure prophylaxis to HIV-1
serodiscordant couples in East Africa: a
qualitative evaluation study in Uganda
2018 Actual Serodiscordant
couples
Uganda
Ware et al. What’s love got to do with it? Explaining
adherence to oral antiretroviral pre-exposure
prophylaxis for HIV-serodiscordant couples
2012 Actual Serodiscordant
couples
Uganda
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with diagnosed HIV a semblance of control, it provided a
means to sustain a desired relationship and/or to have chil-
dren [41]. Similarly, male and female sex workers in Kenya
saw PrEP as a potential “expression of self-love and self-care”
tantamount to “making a choice to live” [27].
3.2 | Navigating the risk environment: perceptions,
realities and compensation
PrEP has the potential to slow HIV transmission in geographic
areas, or in sub-populations, where there remains high HIV
prevalence with low sustained viral suppression, and otherwise
few viable options for prevention. Compared to condoms it is
especially useful for those populations with limited control
over their risk of sexual exposure (as is sometimes the case
for sex workers), or others where there is a sustained risk of
infection is sustained, such as people in serodiscordant rela-
tionships.
For women and girls in patriarchal societies, PrEP may be
the first viable HIV prevention option that they can use on
their own terms. In situations where they struggled to control
exposure to HIV from male partners, and where sex outside
the relationship was a concern, access to PrEP was welcomed
[29], both as a means to manage risk perception and to avoid
actual infection. Even within marriage and during pregnancy,
women worried partners might “bring HIV into the home”
[36,41]. Many women only acknowledged risk of HIV infection
within their primary relationship [31] but fear of rape and
other violence was also cited as a motivator for PrEP use
[25].
In two earlier theoretical studies, concerns about PrEP “re-
placing” or decreasing condom use in general were common
among sex workers [22,34]. However, male and female sex
workers overall were supportive of the idea of PrEP providing
“added protection” even in the context of aspirations to always
use condoms [27]. Additionally, three other papers noted that
risk behaviour did not change over time among participants
actually using PrEP including migrant workers and female
partners, MSM, FSW and serodiscordant couples [36,42,43]. It
should also be noted that two systematic reviews also have
shown no significant changes in behaviour among PrEP users
[1,17].
3.3 | Relationship influences and expectations
Oral PrEP related research has documented how partners of
potential or actual users have significant influence over use, as
has been the case with other products. Condom use, or lack
thereof, is often determined by male partners [44–47], which
was similarly found in microbicide gel studies[37,38]. Indeed,
in a theoretical study about motivations to use PrEP [32]
female participants believed that the tablet would help to alle-
viate challenges they faced in partner condom negotiation.
They described how condoms were a source of conflict in
relationships where men insisted against use and women held
genuine concerns about the risk of acquiring HIV or other
STIs where a partner’s status was unknown or the partner
was suspected of external relationships.
While some have sought to promote antiretroviral (ARV)
based prevention as a female controlled or initiated HIV pre-
vention technology [48,49], several studies have shown that
male partners still often exert considerable influence, either
positive or negative. Carroll et al. examined gender dynamics
within relationships and how these influence decision making
relating to PrEP, identifying a wide variety of experiences [50].
HIV-negative women in their study overwhelmingly reported
that the decision for either partner to initiate ART or PrEP, as
appropriate, belonged entirely to their husbands. HIV-positive
men also reported that they possess the ultimate authority to
make medical decisions for themselves and their spouses. Sim-
ilarly, HIV-negative men expressed frustration with the PrEP
regimen and indicated that the burden of taking medication
had been thrust upon them by their HIV-positive wives [50].
In Roberts et al., 16% of women in their serodiscordant
couple study reported intimate partner violence (IPV) at some
point during the trial [51]. They also had increased risk of low
adherence as assessed by pill count and by plasma tenofovir.
Verbal, economic and physical IPV were all associated with
low adherence. In-depth interviews identified several ways in
which IPV affected adherence, including stress and forgetting,
leaving home without pills, and partners throwing pills away.
Conversely, in a theoretical study, female sex workers articu-
lated fear of violence as a motivator for taking PrEP [34].
Despite these issues, women commonly cited the option of
disclosure as a benefit of PrEP use [16,22,34,52,53], thus
empowering to prevent HIV infection in scenarios where their
partners insist on condomless sex. Indeed, in the Partners
Demonstration Project, PrEP provided additional protection as
a “back-up” mechanism when their partners refused to use
condoms and in cases of condom breakage [54]. However,
other papers identified a wide range of disclosure decisions
and experiences. In their study of PrEP adherence influencing
factors as part of FEM-PrEP, Corneli et al. reported some
male partners of female participants were very supportive and
would remind them to take the pills [31]. Some had partners
who merely acquiesced to their pill use, while a few opted not
to tell their partners at all for fears of negative reaction and
insistence of cessation.
Ware et al. report that while the presence of HIV serodis-
cordance can destabilize a couple, given that the HIV-negative
partner often reacts with anger or fear to the HIV infection
(and the potential infidelity it represents), PrEP can be seen
as a solution [55]. Ultimately it can provide a means of safe-
guarding health without ending the relationship. Simultaneous
use of ARVs by the HIV-positive partner turned management
of HIV into a shared experience, and serodiscordant couple-
focused services (including attending appointments and coun-
selling as a couple) brought partners together, increasing
mutual support through having a space to become educated
and comfortable with PrEP [41,56]. This might suggest a
potential positive impact of PrEP in developing relationship
intimacy, a key aspect of health and well-being that is often
overlooked in public health and social care interventions [57].
Several papers briefly highlighted the complexities of PrEP
monitoring and adherence for people in romantic or regular
relationships. They describe how adherence to PrEP may at
times diminish as a consequence of changing sex patterns
within the relationship, such as reduced libido as a result of
partner absence from the home [29,58]. Some study partici-
pants reported they may wish to cease PrEP use if in a com-
mitted relationship, within which their concern about HIV
transmission would diminish [55]. This should of course be an
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empowered choice for all wishing to start, or stop, PrEP, but
poses challenges for those seeking to utilize stringent mea-
sures of PrEP adherence that do not reflect the reality of
relationships.
3.4 | Efficacy and side effects managing PrEP use
Defining and understanding the concept of ARVs for prevent-
ing HIV is complicated and multi-dimensional, including the
management of potential stigma and understanding efficacy.
For instance, some studies identified that developing an initial
understanding of taking ARVs to prevent HIV remained con-
fusing to study participants even after they had completed a
rigorous informed consent process and had been participating
in the study [21,37]. This emerged as a central issue the trials
showing no efficacy, suggesting that misunderstanding of PrEP
as an efficacious prevention modality may be a significant bar-
rier in scale-up.
Perceived efficacy (i.e. the extent to which PrEP prevents
HIV acquisition) was found to be a significant component of
acceptability among most populations [22,35]. Beliefs about
PrEP efficacy were directly related to whether people could
be sufficiently adherent to the medication, and were influ-
enced by lack of communication or open support from places
of authority (clinics, providers and Ministries of Health) [21].
In efficacy research, the possibility of being on placebo and
the unknown efficacy of the active PrEP pill were directly
linked to lack of use in some studies, pointing to the impor-
tance of highlighting the high efficacy of PrEP in actual service
delivery [37,58,59]. It will be important to capitalize; however,
on the curiosity about PrEP, its novelty and its protective
value if taken consistently, to encourage use among those at
highest risk [23,54].
Side effects, or fear of potential side effects, were common
in both efficacy and implementation studies. Initial side effects
among female partners of migrant mine workers in Mozam-
bique dissipated over time but were tolerated because they
took the side effects to mean that PrEP was working [36].
Concerns about side effects during discussions of theoretical
acceptability were common among women in one study,
including partners in serodiscordant couples, adolescent girls
and young women (AGYW), and sex workers [22]. Sex workers
in Kenya suggested they would prefer intermittent use to
reduce potential side effects over time since they anticipated
a longer period of potential exposure to HIV as a result of
their work [27]. This should also be noted as a potential moti-
vator for intermittent PrEP use.
PrEP could play an important role in safer conception, but
side effects need to be clearly discussed with clients. In one
study, women said they would stop PrEP if trying to conceive
due to worry of how it might affect the foetus [29]. However,
women in the Partners study in Kenya who experienced minor
side effects still affirmed that having an HIV-negative baby
was worth the risk [41].
Finally, it should be noted that a recent meta-analysis sug-
gested that very few major, and limited minor, side effects will
occur when using PrEP [1]. This has been confirmed by multi-
ple demonstration projects where minor side effects were lim-
ited to the first few days/weeks of use [60]. This suggests a
significant disjuncture between the perception of potential
side effects, the attribution of illness to the use of PrEP, and
side effects actually triggered by the medication. Communicat-
ing this to interested, but concerned, end-users should be a
priority for intervention scale-up.
3.5 | Practical considerations for PrEP use
User preferences for specific product attributes and the prac-
ticalities of PrEP use have been widely investigated [16].
These practical considerations remain important in planning
for PrEP scale-up both for service delivery and day-to-day
end-user experiences. Among actual end-users, basic practical-
ities such as clinic access, pill storage and managing adherence
in the context of everyday obligations were significant consid-
erations, as was negotiating with family, schools or employers
to make time for appointments [23,33].
The service delivery environment also played a key role in
successful PrEP implementation. This was a particularly press-
ing issue for key populations who already commonly face
stigma attending health clinics [61]. Fear of rebuke from provi-
ders for not adhering to the medication, or being dropped
from a study as a result, was cited as reason for lying about
adherence [62,63], and points to the need to ensure construc-
tive, open engagement between providers and clients. Open
exchanges and high quality counselling were noted as being of
particular value [32]. Negative clinic experiences directly
deterred PrEP use [21,33], whereas good quality care was
highly valued and increased clinic attendance [33,58]. In the
FEM-PrEP study, repeated HIV-negative tests (even if on pla-
cebo) reinforced the notion that PrEP worked [32,33],
although in another study it was noted that having to test
often for HIV could be a barrier to continued PrEP use [36].
In Kenya and Uganda, women felt that providers play a key
role in supporting PrEP use, especially outside of the trial
environment for women who may not fully understand their
own risk and the benefits of PrEP for conceiving babies free
of HIV [41]. Women in Uganda also worried that the shortage
of doctors/clinical staff could stand in the way of PrEP rollout
due to already limited capacity to deliver existing services
[59]. Importantly, community awareness of PrEP to promote
support for use, access, and coverage has been noted as a
critical component for successful implementation [26,34,41].
Consistent adherence while taking PrEP is the cornerstone
of effective use and yet it was challenging in several of the
efficacy studies to maintain adequate levels of use [1]. Women
in several studies acknowledged forgetting, ambivalence, per-
sonal barriers (travel, family issues), missing clinic visits and
refills, and worry about side effects as reasons for inconsis-
tent use [37,43,58,62]. Similarly, the active management of
actual side effects is an important factor to consider in scale-
up, directly linking with the need for supportive counselling to
encourage consistent use over time. Conflicts with partners
and having to hide pill taking was also reported to cause peo-
ple to forget to take their pills [58].
The use of alcohol and drugs was another concern related
to efficacy and consistent use. This was particularly highlighted
among sex workers, MSM, and young women, where partici-
pants were concerned that PrEP may not protect them from
HIV when using other substances [22,23,34]. These partici-
pants also acknowledged potentially forgetting to take their
pills if they were inebriated. Some potential PrEP users
reported their own prior inability to finish pills (such as
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antibiotics) as a signal they might not be able to successfully
take oral PrEP [23].
Overall, the importance of developing pill taking behaviours
and strategies is paramount to successful use and most have
found manageable solutions [21,36]. Behaviours can be sup-
ported by early, and continued engagement with counsellors
which has been shown to generate consistent use [54]. Inter-
estingly, one older study found that those experiencing more
difficulties in pill taking were more likely to stay in the study
and were also able to develop strategies over time [64].
Related to the supportive environment and intimate relation-
ships, studies that involved serodiscordant couples found the
relationship provided an easier context in which to use PrEP,
as it became a “shared commitment to HIV management and
the relationship” [54] where adherence/use was considered a
“family affair” [59].
Diverse perspectives were shared in relation to alternative,
non-daily PrEP options. For some populations, such as female
partners of migrant miners [36], shorter term use was prefer-
able and intermittent dosing, for when partners were at home,
was appealing.
Some of the papers in this review included theoretical per-
spectives on future products where women expressed prefer-
ences for long-acting PrEP [34,52]. One paper reported how
some women anticipated their preferences would change over
time [39], and some participants expressed wanting to have
systemic protection while others prefer to have drug only in
one area of their bodies [39]. Highlighting the importance of
choice in this VOICE-D ancillary study South Africa, young
women preferred pills which seemed less dangerous and more
trustworthy, while female partners in serodiscordant couples
and sex workers preferred long-acting products which require
less maintenance [22]. These perspectives will be important to
consider within the context of all that has been learned
through oral PrEP implementation to ensure access to a range
of appropriate and relevant interventions and products as
they emerge.
4 | CONCLUSIONS
This review demonstrates the ways in which PrEP can, and
already is, having a significant impact on the personal, rela-
tional, and social lives of HIV affected populations in sub-
Saharan Africa. Those considering investment in and imple-
mentation of PrEP should take note of the robust and
nuanced evidence suggesting great potential for PrEP to
reduce HIV related anxiety, empower people (especially
women) to take control of their sexual health, and to positively
influence relationships (particularly those that are serodiscor-
dant). These are significant benefits playing a role in reducing
new infections.
However, this review also makes clear that the incorpora-
tion of PrEP into everyday lives is not without its challenges.
There are pervasive concerns about side effects, and, to some
extent, that the current required clinical engagement is overly
burdensome. These issues exist in combination with health
services that can be stigmatizing or insufficiently welcoming of
key populations [65]. Uncertainty as to the effectiveness of
PrEP remains especially where ingrained messages featuring
100% condom use has been the focus of HIV prevention
campaigns over several decades. Belief and trust in PrEP will
take time to develop and achieving this will also require the
maintenance of efforts to reduce HIV-related stigma. Several
studies identified how conflation of PrEP as ART and there-
fore being HIV positive could be perceived negatively by part-
ners, family or friends. Through PrEP education and
addressing HIV related stigma we can reduce this concern
and potential barrier.
Notions of risk compensation were not common among the
actual use studies in this review, and reported sexual beha-
viour did not change over time in any of the efficacy trials or
demonstration projects [1,66,67]. However, this has continued
to be a concern expressed from higher level stakeholders.
Rhetoric perpetuating the assumption that PrEP will automati-
cally encourage increased risk-taking behaviours should be
carefully monitored to avoid.
Much of the research to date has emerged within the con-
fines of clinical trials or demonstration projects. As such, some
of the findings reported may be specific to that environment
and may not have (as much) relevance in real-world settings.
Examples include positive feelings towards PrEP in the con-
text of high quality wrap around study services; uncertainties
about efficacy of drugs given where randomization to placebo
was possible; and practical concerns of being seen attending a
trial site often synonymous with HIV treatment. Such issues
may be unavoidable in the shorter-term given the requirement
for rigorous HIV testing but it will be important to mitigate
these issues in longer-term implementation.
Thus far research has been perhaps overly focused on prac-
tical dimensions of adherence (i.e. where pills are kept, how
they are stored etc.). Less often have papers examined how
significant others shape and inform continued PrEP use, espe-
cially the ways in which couples could be supported to effec-
tively negotiate use within their relationship. It is interesting
to note that despite much global level discourse framing PrEP
as emancipatory for women – they finally have an efficacious
female initiated technology to protect themselves from HIV -
it seems there is good evidence that many men still wield sig-
nificant authority over if and how it is used. Given socially and
culturally pervasive gender imbalances, this should not be sur-
prising, and is a reminder to be cognisant of how the notion
of empowerment is communicated.
Notable in their (near complete) absence from this review
are people who use drugs and transgender people. Only one
paper specifically examined the theoretical perspectives of
people who use drugs, and in brief, reports only on a concern
for side effects. Marginally more attention has been paid to
MSM but not the extent that is required given high HIV inci-
dence across the continent [65]. Further research with MSM,
PWUD and transgender people is required to understand
issues such as relational support for PrEP use, stigma that
may be associated with use and how to address it, as well as
the effects of criminalization on access to PrEP and continued
PrEP use. Criminalization of key populations and practices
such as sex work was not specifically addressed in the papers
identified in this review and should be carefully considered as
a significant barrier to PrEP use. Papers outside this review
have also underscored this point [68,69].
This paper describes a scoping review of available research
relating to the experience of using PrEP, or perspectives about
potentially doing so. It presents the extent of evidence and
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summarizes key issues that may influence uptake and contin-
ued use by key populations. It is not, however, a systematic
review or meta-analysis of all available data. Our review was
limited to peer reviewed academic articles and does not
include grey literature. This is a rapidly emerging field of
research and many studies of real-world PrEP use are still
being analysed and disseminated. The paper does, however,
provide a comprehensive overview of significant issues that
have relevance to demand creation, health promotion, and
clinical interventions that aim to increase uptake and effective
use of PrEP.
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